{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:17:12Z","timestamp":1787401032313,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in atherosclerotic lesion progression and acts as an efferocytic molecule in the resolution of advanced plaque. In previous studies, linear azapeptide CD36 ligands were shown to exhibit anti-atherosclerotic properties. In the present study, a novel potent and selective macrocyclic azapeptide CD36 ligand, MPE-298, has proven effective in protecting against atherosclerosis progression. Features of greater plaque stability were observed after 8 weeks of daily injections with the cyclic azapeptide in apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet.<\/jats:p>","DOI":"10.3389\/fphar.2023.1204905","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:19:22Z","timestamp":1685614762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A cyclic azapeptide ligand of the scavenger receptor CD36\/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice"],"prefix":"10.3389","volume":"14","author":[{"given":"Jade","family":"Gauvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Fr\u00e9geau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Elimam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsanullah","family":"Ahsanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Lubell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Marleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e24102","DOI":"10.1002\/pep2.24102","article-title":"Aza-propargylglycine installation by aza-amino acylation: Synthesis and ala-scan of an azacyclopeptide CD36 modulator","volume":"111","author":"Ahsanullah","year":"2019","journal-title":"Peptide Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/cvr\/cvs225","article-title":"EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice","volume":"96","author":"Bessi","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1369\/jhc.2008.952044","article-title":"Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma","volume":"57","author":"Bressenot","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2013.05.031","article-title":"EP 80317, a CD36 selective ligand, promotes reverse cholesterol transport in apolipoprotein E-deficient mice","volume":"229","author":"Bujold","year":"2013","journal-title":"Atherosclerosis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cvr\/cvp118","article-title":"CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages","volume":"83","author":"Bujold","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"11071","DOI":"10.1021\/acs.jmedchem.9b00918","article-title":"Dynamic chirality in the mechanism of action of allosteric CD36 modulators of macrophage-driven inflammation","volume":"62","author":"Danelius","year":"2019","journal-title":"J. Med. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cardiores.2005.11.003","article-title":"Atherosclerosis and proteinase activation","volume":"69","author":"Dollery","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","article-title":"Efferocytosis in health and disease","volume":"20","author":"Doran","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1172\/JCI14006","article-title":"CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism","volume":"108","author":"Febbraio","year":"2001","journal-title":"J. Clin. Invest."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.biocel.2007.03.012","article-title":"CD36: Implications in cardiovascular disease","volume":"39","author":"Febbraio","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2020.06.010","article-title":"Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice","volume":"307","author":"Fr\u00e9geau","year":"2020","journal-title":"Atherosclerosis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/cvr\/cvs301","article-title":"Expansion of necrotic core and shedding of mertk receptor in human carotid plaques: A role for oxidized polyunsaturated fatty acids?","volume":"97","author":"Garbin","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"839248","DOI":"10.3389\/fcell.2022.839248","article-title":"Efferocytosis and its role in inflammatory disorders","volume":"10","author":"Ge","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/cvr\/cvp081","article-title":"The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation","volume":"83","author":"Harb","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cvr\/cvv007","article-title":"Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor","volume":"105","author":"Hu","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.7759\/cureus.9349","article-title":"Global epidemiology of ischemic heart disease: Results from the global burden of disease study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fimmu.2011.00057","article-title":"Modulation of macrophage efferocytosis in inflammation","volume":"2","author":"Korns","year":"2011","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2020.00553","article-title":"Phagocytosis of apoptotic cells in resolution of inflammation","volume":"11","author":"Kourtzelis","year":"2020","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atheroscler","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2023.02.001","article-title":"Cellular mechanisms underlying the impairment of macrophage efferocytosis","volume":"254","author":"Ma","year":"2023","journal-title":"Immunol. Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1096\/fj.04-3253fje","article-title":"EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions","volume":"19","author":"Marleau","year":"2005","journal-title":"FASEB J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"12903","DOI":"10.1038\/s41598-019-49472-8","article-title":"Immunometabolic modulation of retinal inflammation by CD36 ligand","volume":"9","author":"Mellal","year":"2019","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1021\/acs.jmedchem.1c00642","article-title":"Diversity-Oriented A(3)-macrocyclization for studying influences of ring-size and shape of cyclic peptides: CD36 receptor modulators","volume":"64","author":"Ohm","year":"2021","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9263","DOI":"10.1021\/acs.jmedchem.7b01209","article-title":"Influences of histidine-1 and azaphenylalanine-4 on the affinity, anti-inflammatory, and antiangiogenic activities of azapeptide cluster of differentiation 36 receptor modulators","volume":"60","author":"Possi","year":"2017","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1021\/jm300557t","article-title":"Azapeptide analogues of the growth hormone releasing Peptide 6 as cluster of differentiation 36 receptor ligands with reduced affinity for the growth hormone secretagogue receptor 1a","volume":"55","author":"Proulx","year":"2012","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/biomedicines8080241","article-title":"Synthesis and biomedical potential of azapeptide modulators of the cluster of differentiation 36 receptor (CD36)","volume":"8","author":"Proulx","year":"2020","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.RES.0000150046.48115.80","article-title":"Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque: Role of SAF-1 in the induction process","volume":"95","author":"Ray","year":"2004","journal-title":"Circ. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/s0008-6363(98)00321-6","article-title":"Collagen synthesis in atherosclerosis: Too much and not enough","volume":"41","author":"Rekhter","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"33335","DOI":"10.1074\/jbc.M111.263020","article-title":"Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C\u03b4, and p38 mitogen-activated protein kinase (MAPK)","volume":"286","author":"Thorp","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/s0008-6363(98)00276-4","article-title":"Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability","volume":"41","author":"van der Wal","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/ATVBAHA.111.224873","article-title":"Apoptotic cell death and efferocytosis in atherosclerosis","volume":"32","author":"Van Vre","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"585285","DOI":"10.3389\/fendo.2020.585285","article-title":"Potential mechanisms and effects of efferocytosis in atherosclerosis","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/01.atv.0000014587.66321.b4","article-title":"Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice","volume":"22","author":"Williams","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1042\/BST20220441","article-title":"The intracellular signaling pathways governing macrophage activation and function in human atherosclerosis","volume":"50","author":"Wilson","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1164\/rccm.201003-0452OC","article-title":"Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils","volume":"182","author":"Yang","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fcvm.2017.00086","article-title":"Mechanisms and consequences of defective efferocytosis in atherosclerosis","volume":"4","author":"Yurdagul","year":"2017","journal-title":"Front. Cardiovasc. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1002\/anie.201611685","article-title":"Diversity-Oriented synthesis of cyclic azapeptides by A3 -macrocyclization provides high-affinity CD36-modulating peptidomimetics","volume":"56","author":"Zhang","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/ol403297v","article-title":"Multicomponent diversity-oriented synthesis of aza-lysine-peptide mimics","volume":"16","author":"Zhang","year":"2014","journal-title":"Org. Lett."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e60960","DOI":"10.1371\/journal.pone.0060960","article-title":"Tryptase promotes atherosclerotic plaque haemorrhage in ApoE-\/- mice","volume":"8","author":"Zhi","year":"2013","journal-title":"PLoS. One."},{"key":"B42","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1096\/fj.201800223R","article-title":"Myc-nick promotes efferocytosis through M2 macrophage polarization during resolution of inflammation","volume":"32","author":"Zhong","year":"2018","journal-title":"FASEB J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1204905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:19:26Z","timestamp":1685614766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1204905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":42,"alternative-id":["10.3389\/fphar.2023.1204905"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1204905","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1204905"}}